» Articles » PMID: 16258270

Teratogens As Anti-cancer Drugs

Overview
Journal Cell Cycle
Specialty Cell Biology
Date 2005 Nov 1
PMID 16258270
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Most anticancer drugs are teratogens, merely because they target vital cellular functions. Conversely, some plants produce agents that intentionally target embryonic signaling pathways, precisely to cause birth defects if pregnant animals eat such plants. Cyclopamine, a teratogen produced by a flowering plant, inhibits the Hh/Gli pathway, causing developmental defects such as cyclopia (one eye in the middle of the face). In theory, selective teratogens may suppress cancer cells that reactivate embryonic pathways, while sparing most normal cells. I discuss the potential (and limits) of teratogens in cancer therapy, linking diverse topics from morning sickness of pregnancy, embryonic pathways and poisonous plants to the mechanism of action of anticancer teratogens and their combinations with less selective cytotoxic agents.

Citing Articles

Commentary: Nanoparticle-Based Chemotherapy Delivery and Potential Health Risks: Prospects for Effective Clinical Translation.

Assefa D, Melaku T, Alemu S Technol Cancer Res Treat. 2023; 22:15330338231220171.

PMID: 38130152 DOI: 10.1177/15330338231220171.


Inhibition of triple negative breast cancer metastasis and invasiveness by novel drugs that target epithelial to mesenchymal transition.

Garcia E, Luna I, Persad K, Agopsowicz K, Jay D, West F Sci Rep. 2021; 11(1):11757.

PMID: 34083676 PMC: 8175347. DOI: 10.1038/s41598-021-91344-7.


The effect of propolis administration on fetal development.

Fikri A, Sulaeman A, Handharyani E, Marliyati S, Fahrudin M Heliyon. 2019; 5(10):e02672.

PMID: 31687508 PMC: 6820270. DOI: 10.1016/j.heliyon.2019.e02672.


Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX) nude mouse models.

Kawaguchi K, Miyake K, Zhao M, Kiyuna T, Igarashi K, Miyake M Cell Cycle. 2018; 17(16):2019-2026.

PMID: 29963961 PMC: 6224272. DOI: 10.1080/15384101.2018.1480223.


Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model.

Igarashi K, Kawaguchi K, Li S, Han Q, Tan Y, Gainor E Oncotarget. 2018; 9(27):19263-19272.

PMID: 29721200 PMC: 5922394. DOI: 10.18632/oncotarget.24996.